Viking Therapeutics, Inc. financial data

Symbol
VKTX on Nasdaq
Location
9920 Pacific Heights Blvd, Suite 350, San Diego, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Oct 23, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.18K % +1.51%
Debt-to-equity 3.3 % -2.94%
Return On Equity -29.4 % -130%
Return On Assets -28.4 % -131%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 113M shares +1.44%
Common Stock, Shares, Outstanding 112M shares +0.91%
Entity Public Float 4B USD +4174%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 112M shares +1.27%
Weighted Average Number of Shares Outstanding, Diluted 112M shares +1.27%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 222M USD +144%
General and Administrative Expense 52.4M USD +22.3%
Operating Income (Loss) -275M USD -105%
Net Income (Loss) Attributable to Parent -237M USD -139%
Earnings Per Share, Basic -2 USD/shares -132%
Earnings Per Share, Diluted -2 USD/shares -132%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 100M USD +99.4%
Assets, Current 739M USD -21.1%
Operating Lease, Right-of-Use Asset 666K USD -40.2%
Assets 739M USD -21.2%
Accounts Payable, Current 4.41M USD +1637%
Liabilities, Current 26.1M USD +1.49%
Operating Lease, Liability, Noncurrent 318K USD -57.9%
Liabilities 26.4M USD -0.21%
Retained Earnings (Accumulated Deficit) -690M USD -52.5%
Stockholders' Equity Attributable to Parent 713M USD -21.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 713M USD -21.8%
Liabilities and Equity 739M USD -21.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -52.3M USD -753%
Net Cash Provided by (Used in) Financing Activities 349K USD -99.9%
Net Cash Provided by (Used in) Investing Activities 63.2M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 112M shares +0.91%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -18.3M USD -31.2%
Deferred Tax Assets, Valuation Allowance 164M USD +37.9%
Deferred Tax Assets, Gross 164M USD +37.8%
Operating Lease, Liability 755K USD -38.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -239M USD -147%
Operating Lease, Liability, Current 437K USD -8.96%
Operating Lease, Weighted Average Discount Rate, Percent 0.03 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 40.8M USD +55.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 281K USD -10.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%